Results 71 to 80 of about 38,667 (276)
Advanced Functional Materials, EarlyView.A dual‐layer living hydrogel, ProΦGel, integrates bacteriophages and probiotics for synergistic wound infection therapy. The outer gelatin‐based matrix releases phages on demand in response to P. aeruginosa infections, while inner alginate beads sustain probiotic delivery.
Siyuan Tao +6 more
wiley +1 more source
Frontiers in Immunology, 2017 Human immunodeficiency virus (HIV) infects millions of people worldwide, and new cases continue to emerge. Once infected, the virus cannot be cleared by the immune system and causes acquired immunodeficiency syndrome.
Yew Ann Leong +3 more
doaj +1 more source
iScience, 2021 Summary: Highly mutable viruses evolve to evade host immunity that exerts selective pressure and adapts to viral dynamics. Here, we provide a framework for identifying key determinants of the mode and fate of viral-immune coevolution by linking molecular
Jiming Sheng, Shenshen Wang
doaj +1 more source
The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy [PDF]
, 2015 Objective: The objective of this study is to assess the risk of viral rebound in postpartum women on suppressive combination antiretroviral therapy (cART). Methods: Using data from the UK Collaborative HIV Cohort (UK CHIC) study and the UK and Ireland
Huntington, SE
core
Advanced Functional Materials, EarlyView.We present ultrathin flexible transparent electrodes through iCVD‐enabled molecular control of 10 nm gold films on poly(dimethylaminomethylstyrene). In vivo validation demonstrated photoelectric artifact reduction vs. opaque electrodes and preservation of natural neural dynamics.
Tae Jin Mun +11 more
wiley +1 more source
Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. [PDF]
J Clin Invest, 2020 Infusion of the broadly neutralizing antibody VRC01 has been evaluated in individuals chronically infected with HIV-1. Here, we studied how VRC01 infusions affected viral rebound after cessation of antiretroviral therapy (ART) in 18 acutely treated and durably suppressed individuals.
Cale EM +34 more
europepmc +4 more sources
Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring [PDF]
, 2018 Objectives: The resistance profiles of patients receiving long-term ART in sub-Saharan Africa have been poorly described. This study obtained a sensitive assessment of the resistance patterns associated with long-term tenofovir-based ART in a ...
Appiah, Lambert T +9 more
core +3 more sources
Advanced Healthcare Materials, EarlyView.The biomimetic nanoplatform IMNP (ETS1 pDNA/PBAE@ITP‐MM) undergoes targeted disassembly at inflammatory vascular sites to release the ETS1 plasmid (pETS1). This release initiates a cascade of effects that inhibit pathogenic pathways and support immune homeostasis. (Abbreviations: EndMT, endothelial‐to‐mesenchymal transition; EC, endothelial cell; TC, T
Feng Zhang +13 more
wiley +1 more source
Emerging PCR-based techniques to study HIV-1 reservoir persistence [PDF]
, 2020 While current antiretroviral therapies are able to halt HIV-1 progression, they are not curative, as an interruption of treatment usually leads to viral rebound.
Cole, Basiel +4 more
core +2 more sources
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
New England Journal of Medicine, 2016 The discovery of potent and broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) has made passive immunization a potential strategy for the prevention and treatment of HIV infection. We sought to determine whether passive administration of VRC01, a bNAb targeting the HIV CD4-binding site, can safely prevent or delay plasma
Katharine J, Bar +37 more
openaire +2 more sources